About Us /

Below you can find more information about our company

About PepVax, Inc.

Founded in February 2013, PepVax, Inc. is developing Immunotherapy to help patients with Triple Negative Breast Cancer (TNBC) by targeting specific proteins called MAGE A on tumors using our SMARTmid™ Technology.

PepVax, Inc. is an early-stage biotechnology company developing novel immunotherapy biologics to treat various cancers. Our proprietary development methodology along with the patented SMARTmid™ technology allows for a universal candidate that localizes the treatment for increased efficacy, decreased adverse effects, and decreased cost. Our focus is to develop immunotherapy that is more effective but also safer, affordable, and eventually curative.

Our Mission

PepVax, Inc. is dedicated to improving the quality of life by designing, producing and marketing novel immunotherapy candidates for cancer and other greatest unmet medical needs. Through innovation and total commitment, we strive to create value for our patients, our employees and our shareholders.

Meet Our Team

Recent News

June, 2015: Paper published by PepVax describing the Epitope specificity and protein signaling interactions driving epidemic occurrences of Ebola disease. Ebolavirus has as main hosts, humans and nonhuman primates where its pathogenic effects result to serious hemorrhagic fever with lethal...
Read more...

August, 2014: Paper published by PepVax describing a novel strategy of In silico peptide vaccine design for Streptococcus mutans. Several attempts have been made towards the development of a viable vaccine for Streptococcus mutans (S. Mutans). This Gram positive bacterium is..."
Read more...

TEDCO Press Release: Maryland Entrepreneur List Success Story
Read more...

Washington Business Journal: Can Indiegogo fund biotech? PepVax bets on it
Read more...